Before the insult: Why the microglial starting state matters in neurodegeneration
Abstract
Microglia have a past. Our experiments do not always capture it. Much of what we know about microglia in neurodegeneration comes from cells observed after they have already encountered a challenge: proteins have aggregated, neurons have become stressed, myelin has been damaged, inflammatory signals have appeared, or the organism has simply grown old. We then describe the resulting microglial states with increasing molecular precision and ask what disease did to microglia. Yet there is a deceptively simple problem: the response we observe depends not only on the insult, but also on the cell that received it. Here, I propose that the microglial starting state, i.e. the molecular and functional configuration of microglia immediately before the event whose consequences we seek to understand, may influence neurodegenerative trajectories and should be explicitly considered when interpreting experimental outcomes. Starting states may be genetically encoded, progressively accumulated, shaped by inflammatory or immune memory, or imposed by the current tissue and physiological context. Importantly, they need not be obvious at baseline. Their most meaningful property may instead be the range of responses that remains accessible when the next challenge arrives. This perspective has consequences beyond experimental design. If starting states contain information about future responses, they could ultimately contribute to neuroimmune endotyping, prognosis, prediction of treatment response and therapeutic redirection. Rather than asking only “ what does disease do to microglia?” , we may need to ask “ what do microglia bring into disease? ”
Related
- PSYCHIATRY The Case for Starting Over
- Colchicine use and cardiovascular event risk in Chinese adults starting urate-lowering therapy: a cohort study
- A Fatal Case of Disseminated Mucormycosis in a Patient Shortly after Starting Treatment against Malignant Lymphoma
- Patients' perceptions on HIV testing and starting antiretroviral therapy during implementation of universal test and treat.
- The Next Frontier in Person-Centered Diabetes Care—From Asking What Matters to Acting on What Matters
BibTeX
@article{szelechowski2026before,
title = {{Before the insult: Why the microglial starting state matters in neurodegeneration}},
author = {Marion Marion Szelechowski},
journal = {Glial Health Research},
year = {2026},
month = oct,
doi = {10.1016/j.ghres.2026.100022},
url = {https://hal.science/hal-05793818v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Before the insult: Why the microglial starting state matters in neurodegeneration
AU - Marion Marion Szelechowski
PY - 2026
DA - 2026/10/12
JO - Glial Health Research
DO - 10.1016/j.ghres.2026.100022
UR - https://hal.science/hal-05793818v1
AB - Microglia have a past. Our experiments do not always capture it. Much of what we know about microglia in neurodegeneration comes from cells observed after they have already encountered a challenge: proteins have aggregated, neurons have become stressed, myelin has been damaged, inflammatory signals have appeared, or the organism has simply grown old. We then describe the resulting microglial states with increasing molecular precision and ask what disease did to microglia. Yet there is a deceptively simple problem: the response we observe depends not only on the insult, but also on the cell that received it. Here, I propose that the microglial starting state, i.e. the molecular and functional configuration of microglia immediately before the event whose consequences we seek to understand, may influence neurodegenerative trajectories and should be explicitly considered when interpreting experimental outcomes. Starting states may be genetically encoded, progressively accumulated, shaped by inflammatory or immune memory, or imposed by the current tissue and physiological context. Importantly, they need not be obvious at baseline. Their most meaningful property may instead be the range of responses that remains accessible when the next challenge arrives. This perspective has consequences beyond experimental design. If starting states contain information about future responses, they could ultimately contribute to neuroimmune endotyping, prognosis, prediction of treatment response and therapeutic redirection. Rather than asking only “ what does disease do to microglia?” , we may need to ask “ what do microglia bring into disease? ”
SN - 2950-4074
SN - 2950-4074
ER -